QNCX
Quince Therapeutics, Inc.
NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY
$1.31
+6.50% today
Updated 2026-04-30
Market cap
$20.05M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-16.80
Dividend yield
—
52W range
$1 – $46
Volume
63.6M
Quince Therapeutics, Inc. (QNCX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | $45000.00 | $51000.00 | $188000.00 | $332000.00 | $344000.00 | $175000.00 | $322000.00 | $186000.00 | $142000.00 |
| Gross profit | $-45000.00 | $-51000.00 | $-188000.00 | $-332000.00 | $-344000.00 | $-175000.00 | $-322000.00 | $-186000.00 | $-142000.00 |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $9.10M | $10.09M | $30.21M | $61.31M | $60.80M | $25.18M | $9.45M | $18.59M | $35.38M |
| SG&A | $1.27M | $2.03M | $8.95M | $17.59M | $29.52M | $26.01M | $17.70M | $17.58M | $15.05M |
| Operating income | $-10.37M | $-12.12M | $-39.17M | $-78.89M | $-90.32M | $-52.02M | $-34.62M | $-57.28M | $-50.43M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | $-10.32M | $-12.07M | $-38.98M | $-78.56M | $-89.97M | $-50.99M | $-26.82M | $-35.98M | $-50.29M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-10.37M | $-12.12M | $-39.17M | $-78.89M | $-90.32M | $-51.19M | $-27.14M | $-36.17M | $-50.43M |
| Interest expense | $1.64M | $957000.00 | $2.19M | $2.04M | $373000.00 | $568000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.23M | $-12.48M | $-36.98M | $-76.85M | $-89.94M | $-51.66M | $-31.39M | $-56.83M | $-83.98M |
| Net income growth (YoY) | — | -2.0% | -196.4% | -107.8% | -17.0% | +42.6% | +39.2% | -81.1% | -47.8% |
| Profit margin | — | — | — | — | — | — | — | — | — |